ZA200302610B - Propionic acid derivatives with PPAR-alpha activating properties - Google Patents
Propionic acid derivatives with PPAR-alpha activating properties Download PDFInfo
- Publication number
- ZA200302610B ZA200302610B ZA200302610A ZA200302610A ZA200302610B ZA 200302610 B ZA200302610 B ZA 200302610B ZA 200302610 A ZA200302610 A ZA 200302610A ZA 200302610 A ZA200302610 A ZA 200302610A ZA 200302610 B ZA200302610 B ZA 200302610B
- Authority
- ZA
- South Africa
- Prior art keywords
- group
- alkyl
- compounds
- represents hydrogen
- general formula
- Prior art date
Links
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 title description 2
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 title description 2
- 150000005599 propionic acid derivatives Chemical class 0.000 title description 2
- 102000023984 PPAR alpha Human genes 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 79
- 239000001257 hydrogen Substances 0.000 claims description 68
- 229910052739 hydrogen Inorganic materials 0.000 claims description 68
- -1 furanylmethyl Chemical group 0.000 claims description 59
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 46
- 125000004432 carbon atom Chemical group C* 0.000 claims description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 27
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 239000011737 fluorine Substances 0.000 claims description 13
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 11
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 239000000460 chlorine Substances 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 9
- 150000004677 hydrates Chemical class 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 9
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 8
- 229910052801 chlorine Inorganic materials 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 7
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 229910052684 Cerium Inorganic materials 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 3
- WTGULPIOCRAFHN-UHFFFAOYSA-N COClOC(F)(F)F Chemical compound COClOC(F)(F)F WTGULPIOCRAFHN-UHFFFAOYSA-N 0.000 claims description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 3
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 3
- 206010014486 Elevated triglycerides Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000029936 alkylation Effects 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- NRNFVPWVQAOXTC-UHFFFAOYSA-N trifluoro(dimethoxy)-lambda5-chlorane Chemical compound COCl(OC)(F)(F)F NRNFVPWVQAOXTC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 150000003254 radicals Chemical class 0.000 description 15
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 239000002585 base Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 150000001733 carboxylic acid esters Chemical class 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000004430 oxygen atom Chemical group O* 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 238000007257 deesterification reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 229940125753 fibrate Drugs 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000011736 potassium bicarbonate Substances 0.000 description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000005270 trialkylamine group Chemical group 0.000 description 2
- JVVXZOOGOGPDRZ-UHFFFAOYSA-N (1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl)methanamine Chemical compound NCC1(C)CCCC2(C)C3=CC=C(C(C)C)C=C3CCC21 JVVXZOOGOGPDRZ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- JCJODSMQBXMELN-UHFFFAOYSA-N 2-ethyl-5-phenyl-1,2-oxazol-2-ium Chemical compound O1[N+](CC)=CC=C1C1=CC=CC=C1 JCJODSMQBXMELN-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- MPSXGPCFLAGJOM-UHFFFAOYSA-M 2-tert-butyl-5-methyl-1,2-oxazol-2-ium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.CC1=CC=[N+](C(C)(C)C)O1 MPSXGPCFLAGJOM-UHFFFAOYSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001701 chloroform Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000035879 hyperinsulinaemia Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical class C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl chloride Substances ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008275 solid aerosol Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
p WO002/28821 PCT/EP01/11005
Propionic acid derivatives
The present invention relates to novel potent PPAR-alpha-activating compounds for treating, for example, coronary heart disease, and to their preparation.
In spite of many successful therapies, coronary heart disease (CHD) remains a serious public health problem. Treatment with statins, which inhibit HMG-CoA reductase, successfully lowers both LDL cholesterol plasma concentrations and the mortality of patients at risk; however, convincing treatment strategies for the therapy of patients having an unfavourable HDL/LDL cholesterol ratio or hypertriglyceridaemia are still not available to date.
Currently, fibrates are the only therapy option for patients of these risk groups. They act as weak agonists of the peroxisome-proliferator-activated receptor (PPAR )-alpha (Nature 1990, 347, 645-50). A disadvantage of the fibrates which have hitherto been approved is that their interaction with the receptor is only weak, requiring high daily doses and causing considerable side-effects.
WO 00/23407 describes PPAR modulators for treating obesity, atherosclerosis and/or diabetes.
It was an object of the present invention to provide novel compounds which can be used as PPAR-alpha modulators.
It has now been found that this object is achieved by compounds of the general formula (I)
o z -2-
Oo
RY 6 R® RY X 2 RAR OR"
R N RY R'?
N SA ,
Rr’ | , R10
R" R in which
A represents a bond or represents a -CH;- or -CH,CH,- group,
X represents O, S or CH»,
R', R? and R® are identical or different and independently of one another each represents hydrogen, (Ci-Ce)-alkyl, (C3-Cy)-cycloalkyl, hydroxyl, (Ci-Ce)- oO C10 alkoxy, (Cs-Cio)-aryloxy, halogen, trifluoromethyl, trifluoromethoxy, (C;-Ce)- alkylaminosulphonyl, nitro or cyano, or
R' and R? are attached to two adjacent carbon atoms and together with these form a fused cyclohexane or benzene ring, the latter optionally being substituted by a (C,-Cy)-alkylsulphonylmethyl group, and
R? is as defined above,
R* represents hydrogen or (C;-Cq)-alkyl,
R® and R® represent hydrogen or together with the carbon atom to which they are attached form a carbonyl group,
y
J -3-
R’ represents hydrogen, (C;-Cg¢)-alkyl, phenyl or benzyl, where the aromatic radicals mentioned for their part may in each case be mono- to trisubstituted by identical or different substituents from the group consisting of (C;-Ce)- alkyl, (C1-Ce)-alkoxy, hydroxyl and halogen, : 5
R® represents hydrogen, (Cg-Cig)-aryl or represents (C;-C4)-alkyl which for its part may be substituted by hydroxyl, trifluoromethoxy, (C,-C,)-alkoxy or phenoxy, which for their part are optionally mono- or disubstituted by trifluoromethyl, or by (Cs-Ci¢)-aryl or 5- or 6-membered heteroaryl having up to three heteroatoms from the group consisting of N, O and S, where all aryl and hetaroaryl rings mentioned may for their part in each case be mono- to trisubstituted by identical or different substituents from the group consisting
Co of halogen, hydroxyl, (C-Ce)-alkyl, (C-Ce)-alkoxy, trifluoromethyl, oo trifluoromethoxy, cyano, nitro and amino,
R’ and R'? are identical or different and independently of one another each represents hydrogen, (C;-Ce)-alkyl, (C;-Cs)-alkoxy, trifluoromethyl, trifluoromethoxy or halogen,
R'" and R" are identical or different and independently of one another each represents hydrogen or (C,-Ce)-alkyl or together with the carbon atom to which they are attached form a (C4-C5)-cycloalkyl ring, and
RY represents hydrogen or represents a group which can hydrolysed and degraded to the corresponding carboxylic acid, and their pharmaceutically acceptable salts, hydrates and solvates,
b]
J -4- which have pharmacological action and can be used as medicaments or for preparing medicament formulations.
In the context of the invention, a hydrolysable group in the definition of R" is a group which, in particular in the body, leads to a conversion of the -C(0)ORP grouping into the corresponding carboxylic acid (R!? = hydrogen). Such groups are, by way of example and by way of preference: benzyl, (C,-Ce)-alkyl or (C;-Cs)- cycloalkyl which are in each case optionally mono- or polysubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, amino, (C1-Ce)-alkoxy, carboxyl, (C;-Cs)-alkoxycarbonyl, (C,-C¢)-alkoxycarbonylamino and (Ci-Ceg)-alkanoyloxy, and in particular (C;-Cs)-alkyl which is optionally mono- or polysubstituted by identical or different substituents from the group consisting of } B halogen, hydroxyl, amino, (C,;-Cj)-alkoxy, carboxyl, (Cj-Cs)-alkoxycarbonyl, = (C1-C4)-alkoxycarbonylamino and (C;-C4)-alkanoyloxy.
In the context of the invention, (C;-Ce)-alkyl and (C;-Cs)-alkyl represent a straight- chain or branched alkyl radical having 1 to 6 or 1 to 4 carbon atoms, respectively.
Preference is given to a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. The following radicals may be mentioned by way of example and by way of preference: methyl, ethyl, n-propyl, isopropyl and tert-butyl.
In the context of the invention, (Cs-Cio)-aryl represents an aromatic radical having 6 to 10 carbon atoms. A preferred example is the aryl radical phenyl.
In the context of the invention, (C;-Cs)-cycloalkyl and (C4-Cy)-cycloalkyl represent a cycloalkyl group having 3 to 8 and 4 to 7 carbon atoms, respectively. The following radicals may be mentioned by way of example and by way of preference: cyclobutyl, cyclopentyl and cyclohexyl.
In the context of the invention, (C;-Ce)-alkoxy represents a straight-chain or branched alkoxy radical having 1 to 6 carbon atoms. Preference is given to a straight-chain or i”
N -5- branched alkoxy radical having 1 to 4 carbon atoms. The following radicals may be mentioned by way of example and by way of preference: methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
In the context of the invention, (C¢-Cig)-aryloxy represents an aromatic radical having 6 to 10 carbon atoms which is attached via an oxygen atom. A preferred example is the aryloxy radical phenoxy.
In the context of the invention, (C,-C¢)-alkoxycarbonyl represents a straight-chain or branched alkoxy radical having 1 to 6 carbon atoms which is attached via a carbonyl group. Preference is given to a straight-chain or branched alkoxycarbonyl radical having 1 to 4 carbon atoms. The following radicals may be mentioned by way of
CL example and ..by way of - preference: methoxycarbonyl, ethoxycarbonyl, : n-propoxycarbonyl, isopropoxycarbonyl and tert-butoxycarbonyl.
In the context of the invention, (C;-Ce)-alkoxycarbonylamino represents an amino group having a straight-chain or branched alkoxycarbonyl substituent which has 1 to 6 carbon atoms in the alkoxy radical and is attached via the carbonyl group.
Preference is given to an alkoxycarbonylamino radical having 1 to 4 carbon atoms.
The following radicals may be mentioned by way of example and by way of preference: methoxycarbonylamino, ethoxycarbonylamino, n-propoxycarbonylamino, isopropoxycarbonylamino and tert-butoxycarbonylamino.
In the context of the invention, (C;-Ce)-alkanoyloxy represents a straight-chain or branched alkyl radical having 1 to 6 carbon atoms which carries a doubly attached oxygen atom in the 1-position and is attached in the 1-position via a further oxygen atom. The following radicals may be mentioned by way of example and by way of preference: acetoxy, propionoxy, n-butyroxy, i-butyroxy, pivaloyloxy, n-hexanoyloxy.
Pp r, -6-
In the context of the invention, (C;-Ce)-alkylaminosulphonyl represents an amino group which is attached via a sulphonyl group and has a straight-chain or branched alkyl substituent having 1 to 6 carbon atoms. Preference is given to an alkylaminosulphonyl radical having 1 to 4 carbon atoms. The following radicals may be mentioned by way of example and by way of preference: methylaminosulphonyl, ethylaminosulphonyl, n-propylaminosulphonyl, isopropylaminosulphonyl and tert- butylaminosulphonyl.
In the context of the invention, halogen represents fluorine, chlorine, bromine and todine. Preference is given to chlorine or fluorine.
In the context of the invention, 5- or 6-membered heteroaryl having up to 3
CL heteroatoms selected from the group consisting of S, N and O generally representsa ~~ monocyclic heteroaromatic radical which is attached via a ring carbon atom of the heteroaromatic radical, or, if appropriate, via a ring nitrogen atom of the heteroaromatic radical. The following radicals may be mentioned by way of example and by way of preference: furanyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl. Preference is given to furanyl, thienyl and oxazolyl.
Depending on the substitution pattern, the compounds according to the invention can exist in stereoisomeric forms which are either like image and mirror image (enantiomers) or which are not like image and mirror image (diastereomers). The invention relates both to the enantiomers or diastereomers and to their respective mixtures. The racemic forms, like the diastereomers, can be separated in a known manner into the stereoisomerically uniform components.
Furthermore, certain compounds may be present in tautomeric forms. This is known to the person skilled in the art, and such compounds are likewise included within the scope of the invention.
The compounds according to the invention can also be present as salts. In the context of the invention, preference is given to physiologically acceptable salts.
Physiologically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids. Preference is given to salts with organic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulphuric acid or to salts with organic carboxylic or sulphonic acids such as, for example, acetic acid, propionic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulphonic acid, ethanesulphonic acid, benzenesulphonic acid, toluenesulphonic acid or naphthalene- disulphonic acid.
Physiologically acceptable salts can also be salts of the compounds according to the ~~ invention with bases, such as, for example, metal or ammonium salts. Preferred examples are alkali metal salts (for example sodium salts or potassium salts), alkaline earth metal salts (for example magnesium salts or calcium salts), and also ammonium salts which are derived from ammonia or organic amines, such as, for example, ethylamine, di- or triethylamine, ethyldiisopropylamine, monoethanolamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, dibenzylamine,
N-methylmorpholine, dihydroabietylamine, I-ephenamine, methylpiperidine, arginine, lysine, ethylenediamine or 2-phenylethylamine.
The compounds according to the invention can also be present in the form of their solvates, in particular in the form of their hydrates.
Preference is given to compounds of the general formula (I), in which
A represents a bond or represents a -CH,- or -CH,CH,- group,
J -8-
X represents O, S or CH,,
R', R? and R? are identical or different and independently of one another each represents hydrogen, (C;-Ce)-alkyl, (C;-Cg)-alkoxy, hydroxyl, halogen, tri- fluoromethyl, trifluoromethoxy, nitro or cyano,
R* represents hydrogen or (C,-Cy)-alkyl,
R® and R® each represents hydrogen or together with the carbon atom to which they are attached form a carbonyl group,
R’ represents hydrogen, {C;-Ce)-alkyl, phenyl or benzyl, in which the aromatic
So oo radicals mentioned for their part may in each case be mono- to trisubstituted - by identical or different substituents from the group consisting of (C;-Cg)- alkyl, (C;-Cg)-alkoxy, hydroxyl or halogen,
R® represents hydrogen, (Ce-Cyo)-aryl or (C;-Cs)-alkyl, which for its part is optionally substituted by (Cs-Cio)-aryl or 5- or 6-membered heteroaryl having up to three heteroatoms from the group consisting of N, O and S, where all of the ring systems mentioned may for their part in each case be mono- to trisubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, (C;-C¢)-alkyl, (C;-Ce)-alkoxy, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino,
R® and R" are identical or different and independently of one another each represents hydrogen, (C4-Ce)-alkyl, (C;-C¢)-alkoxy, trifluoromethyl, trifluoromethoxy or halogen,
R'! and R" are identical or different and independently of one another each represents hydrogen or (C;-Cq)-alkyl, or together with the carbon atom to which they are attached they form a (Cs-C;)-cycloalkyl ring,
and
RP represents hydrogen or a group that can be hydrolysed and degraded to the : 5 corresponding carboxylic acid, and their pharmaceutically acceptable salts, hydrates and solvates.
Particular preference is given to compounds of the general formula (I), in which
A represents a -CHy- or -CH,CH,- group, - Co
X represents O, S or CH,,
R', R* and R® are identical or different and independently of one another each represents hydrogen, (C;-Cy4)-alkyl, (C;-Cy)-alkoxy, chlorine, fluorine, tri- fluoromethyl, trifluoromethoxy, nitro or cyano,
R* represents hydrogen or methyl,
R® and R® each represent hydrogen or together with the carbon atom to which they are attached form a carbonyl group,
Rr’ represents hydrogen, (C;-Cy)-alkyl or benzyl,
R® represents hydrogen, phenyl, benzyl or 5-membered heteroarylmethyl having up to two heteroatoms from the group consisting of N, O and S, where the aromatic ring systems mentioned for their part may in each case be mono- to trisubstituted by identical or different substituents from the group consisting of chlorine, fluorine, bromine, hydroxyl, (C;-Cs)-alkyl, (C,-C4)-alkoxy, trifluoromethyl and amino,
R’ and R" are identical or different and independently of one another each represents hydrogen, (C;-Cs)-alkyl, (C;-Cs)-alkoxy, trifluoromethyl, fluorine or chlorine,
R!' and R'" are identical or diffferent and independently of one another each represents hydrogen, methyl or ethyl, or together with the carbon atom to which they are attached they form a cyclopentyl or cyclohexyl ring, and
B R" represents hydrogen or represents a group that can be hydrolysed and =~ ~~ degraded to the corresponding carboxylic acid, and their pharmaceutically acceptable salts, hydrates and solvates.
Very particular preference is given to compounds of the general formula (I), in which
A represents a -CH;- or -CH,CH,- group,
X represents O, S or CH,
R! represents hydrogen, methyl or methoxy,
R? and R? are identical or different and independently of one another each represents methyl, trifluoromethyl, methoxy, trifluoromethoxy, chlorine or fluorine,
R* represents hydrogen,
R® and R® together with the carbon atom to which they are attached form a carbonyl group,
R’ represents methyl, ethyl, n-propyl or, in particular, hydrogen,
R® represents phenyl, furanylmethyl or thienylmethyl, where the ring systems mentioned for their part may in each case be mono- or disubstituted by identical or different substituents from the group consisting of methyl and ethyl,
R’® and R" are identical or different and each represents hydrogen or methyl in
SL __particular hydrogen, ~~ - IE - Co
R" and R" are identical or different and each represents hydrogen or methyl in particular methyl, and
R"® represents a group which can be hydrolysed and degraded to the corresponding carboxylic acid, or, in particular, represents hydrogen, and their pharmaceutically acceptable salts, hydrates and solvates.
The general or preferred radical definitions listed above apply both to the end products of the formula (I) and, correspondingly, to the starting materials and intermediates required in each case for the preparation.
The individual radical definitions given in the respective combinations or preferred combinations of radicals are, independently of the respective given combination of radicals, also replaced by any radical definitions of other combinations.
Of particular importance are compounds of the formula (I) in which R* is hydrogen.
Of particular importance are compounds of the formula (I) in which R® and R® together with the carbon atom to which they are attached form a carbonyl group.
Of particular importance are compounds of the formula (I) in which
R! represents hydrogen, methyl or methoxy, and ~_____ __ R?andR: are identical or different and independently of one another each represents ~~ 7 methyl, isopropyl, tert-butyl, cyclohexyl, trifluoromethyl, methoxy, trifluoromethoxy, chlorine or fluorine.
Of particular importance are compounds of the formula (I) in which
R® represents phenyl, furanylmethyl, thienylmethyl or oxazolylmethyl, where the ring systems mentioned for their part may in each case be mono- or disubstituted by methyl, or represents 2-methoxyethyl.
Of very particular importance are compounds of the formula (IA)
RY i 8 X
R2 Q ) >on
Jn H,C CH, (1A), . N A
R’ H in which
A represents a -CH,- or -CH,CH>- group,
X represents O or S,
R! represents hydrogen, methyl or methoxy,
R? and R? are identical or different and independently of one another each represents methyl, isopropyl, tert-butyl, cyclohexyl, trifluoromethyl, methoxy, trifluoro- methoxy, chlorine or fluorine, and wo - RE represents phenyl, furanylmethyl, thienylmethyl or oxazolylmethyl, where the ~~ ring systems mentioned for their part may in each case be mono- or disubstituted by methyl, or represents 2-methoxyethyl.
Moreover, we have found a process for preparing the compounds of the general formula (I) according to the invention, characterized in that [A] compounds of the general formula (II)
RY 1 8 X
Pats 11 12 10
R’ R in which
A,X, R"R® R’, R' R" and R'? are each as defined above and
T represents benzyl, (C;-Ce)-alkyl or a polymeric support suitable for solid-phase synthesis, are initially, with activation of the carboxylic acid group in (II), reacted with compounds of the general formula (IIT)
R! 2
SP (Im), i. NH, in which
R', R? and R3 are each as defined above, to give compounds of the general formula (Ia) 0) .
R =? RS X 2 oO o-T
R \ rR" R"
STONY A
R LY R in which
AX, T,RLURYL RR RE R, R'% R!" and R'? are each as defined above, or [B] compounds of the general formula (IV)
RY 1 ¥ ont
HN R'"" R"™ Iv), : A R10 in which
A,X, T,R%, R®, R!% R!" and R'? are each as defined above, are, in the presence of a base, reacted with compounds of the general formula
V) rR!
R? 7 yo v),
H
R UY in which
R, R2, R3 and R’ are each as defined above and
Q is a suitable leaving group, for example halogen, mesylate or tosylate, preferably bromine or iodine, likewise to compounds of the general formula (Ia)
the compounds of the general formula (Ia) are, if appropriate according to known methods for amide alkylation or amide reduction, converted into compounds of the general formula (Ib) 0)
R\ s RY x 2 RRR o-T
R N rR" R'?
JEON “A (I),
R | a 7 Rr"
R R in which
AX T, R', R?, R’, RY, R%, RS R7, R® R%, R", R'! and R"? are each as defined above then converted with acids or bases into the corresponding carboxylic acids of the general formula (Ic) 0)
R s RX x 2 RR RR OH
N SA (Ic),
R3 l, , R10
R R in which
A,X, RL RE RY RY R® RS R7, RE, R®, R'® R!" and R'? are each as defined above, and these are, if appropriate according to known methods for esterification, modified further by reaction with compounds of the general formula (VI)
RP-Z (VD,
in which
R" is as defined above and
Z represents a suitable leaving group for example halogen, mesylate or tosylate or represents a hydroxyl group.
The process according to the invention is generally carried out at atmospheric pressure. However, it is also possible to carry out the process under elevated pressure or under reduced pressure (for example in a range of from 0.5 to 5 bar).
Solvents which are suitable for the process are customary organic solvents which do not change under the reaction conditions. These include ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons, such as benzene, toluene, xylene, hexane, cyclohexane or mineral oil fractions, or halogenated hydrocarbons, such as dichloromethane, trichloromethane, carbon tetrachloride, dichloroethylene, trichloroethylene or chlorobenzene, or ethyl acetate, pyridine, dimethyl sulphoxide, dimethylformamide, N,N’-dimethylpropyleneurea (DMPU),
N-methylpyrrolidone (NMP), acetonitrile, acetone or nitromethane. It is also possible to use mixtures of the solvents mentioned.
Solvents which are preferred for process step (II) + (IIT) — (Ia) are dichloromethane and dimethylformamide. For process step (IV) + (V) — (la), preference is given to dimethylformamide.
The process step (II) + (II) — (Ia) according to the invention is generally carried out in a temperature range of from 0°C to +100°C, preferably from 0°C to +40°C. The process step (IV) + (V) — (Ia) is generally carried out in a temperature range of from 0°C to +120°C, preferably from +50°C to +100°C.
The auxiliaries used for the amide formation in process step (II) + (II) — (la) are preferably customary condensing agents, such as carbodiimides, for example, N,N'- diethyl-, N,N'-dipropyl-, N,N'-diisopropyl-, N,N'-dicyclohexylcarbodiimide (DCC),
N-(3-dimethylaminoisopropyl)-N'-ethylcarbodiimide hydrochloride (EDC), or carbonyl compounds, such as carbonyldiimidazole, or 1,2-oxazolium compounds, such as 2-ethyl-5-phenyl-1,2-oxazolium 3-sulphate or 2-tert-butyl-5-methyl-isoxa- zolium perchlorate, or acylamino compounds, such as 2-ethoxy-1-ethoxycarbonyl- 1,2-dihydroquinoline, or propanephosphonic anhydride, or isobutyl chloroformate, or bis-(2-ox0-3-oxazolidinyl)-phosphoryl chloride or benzotriazolyloxy-tris(dimethyl- amino)phosphonium hexafluorophosphate, or O-(benzotriazol-1-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (HBTU), 2-(2-oxo0-1-(2H)-pyridyl)-1,1,3,3- ~~ + tetramethyluronium - tetrafluoroborate - (TPTU) or O-(7-azabenzofriazol-1-yl)- =~
N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), if appropriate in combination with further auxiliaries such as 1-hydroxybenzotriazole or N- hydroxysuccinimide, and the bases used are preferably alkali metal carbonates, for example sodium carbonate or bicarbonate or potassium carbonate or bicarbonate, or organic bases, such as trialkylamines, for example triethylamine, N-methyl- morpholine, N-methylpiperidine or diisopropylethylamine. Particular preference is given to the combination of EDC, N-methylmorpholine and 1-hydroxybenzotriazole, of EDC, triethylamine and 1-hydroxybenzotriazole and of HATU and diisopropylethylamine.
Suitable bases for the reaction (IV) + (V) — (Ia) are the customary inorganic bases, such as alkali metal alkoxides, such as, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide, alkali metal carbonates or alkaline earth metal carbonates, such as sodium carbonate, potassium carbonate, calcium carbonate or cesium carbonate, or sodium bicarbonate or potassium bicarbonate, or organic bases, such as trialkylamines, for example triethylamine, N-methylmorpholine, N-methy]- piperidine or diisopropylethylamine. Preference is given to sodium bicarbonate.
The hydrolysis of the carboxylic acid esters in the process step (Ia) or (Ib) — (Ic) is carried out by customary methods by treating the esters in inert solvents with bases, the salts that are initially formed being converted by treatment with acid into the free carboxylic acids. In the case of the tert-butyl esters, the hydrolysis is preferably carried out using acids.
Suitable solvents for the hydrolysis of the carboxylic acid esters are water or the organic solvents which are customary for ester cleavage. These preferably include alcohols, such as methanol, ethanol, propanol, isopropanol or butanol, or ethers, such as tetrahydrofuran or dioxane, dimethylformamide, dichloromethane or dimethyl sulphoxide. It is also possible to use mixtures of the solvents mentioned. Preference is given to water/tetrahydrofuran and, in the case of the reaction with trifluoroacetic ~~ —==--.. - acid, to dichloromethane and, in the case of hydrogen chloride, to tetrahydrofuran, ~~ ~~ diethyl ether, dioxane or water.
Bases suitable for the hydrolysis are the customary inorganic bases. These preferably include alkali metal hydroxide or alkaline earth metal hydroxide, such as, for example, sodium hydroxide, lithium hydroxide, potassium hydroxide or barium hydroxide, or alkali metal carbonates, such as sodium carbonate or potassium carbonate, or sodium bicarbonate. Particular preference is given to using sodium hydroxide or lithium hydroxide.
Suitable acids are, in general, trifluoroacetic acid, sulphuric acid, hydrogen chloride, hydrogen bromide and acetic acid, or mixtures thereof, if appropriate with addition of water. Preference is given to hydrogen chloride or trifluoroacetic acid in the case of the tert-butyl esters and to hydrochloric acid in the case of the methyl esters.
In the case of compounds of the general formula (Ia) or (Ib) prepared by solid-phase synthesis and attached to a polymeric support via the carboxylic acid group, the cleavage from the resin to give the compounds of the general formula (Ic) is likewise carried out by the above-described customary methods for carboxylic acid ester hydrolysis. Here, preference is given to using trifluoroacetic acid.
When carrying out the hydrolysis, the base or the acid is generally employed in an amount of from 1 to 100 mol, preferably from 1.5 to 40 mol, based on 1 mole of the ester.
The hydrolysis is generally carried out in a temperature range of from 0°C to +100°C, preferably from 0°C to +50°C.
The compounds of the general formula (II) are novel, and they can be prepared by initially [a] reacting compounds of the general formula (VII)
RY i
X
A rR" R” (VID,
HB 10
R in which
X, T, R%, R', R" and R'? are each as defined above and
B represents a bond or a methylene group in the presence of a suitable reducing agent with compounds of the general formula (VII)
s -21-
R“NH, (VI), in which
R' [a1] has the meaning of R® given above or 0 [a-2] represents a group of the formula Riot
R in which oo Rr is as defined above ~~ oo and
RY represents (C;-Cy)-alkyl or trimethylsilyl, to give compounds of the general formula (IX) 0 0]
R X
Cour
R™ 11 12 (IX),
SN B R R
H R10 in which
B,X, T, R’, rR, RY, R'2 and R™ are each as defined above, then reacting these compounds in the presence of a base with compounds of the general formula (X)
zs -22-
RY (X), in which
R'® in the case of process variant [a-1] represents a group of the formula 0
R'™ 0?
R in which R” and R'® are each as defined above or, in the case of process variant [a-2] has the meaning of R® given above and
Y represents a suitable leaving group, such as, for example halogen, mesylate or tosylate, preferably bromine or iodine, to give compounds of the general formula (XI) : RS 0 7 X
R o-T 15__ 11 12
R og R R 0:0) 8 H R' 0 R in which
B,X, T,R7, R® R® R'%, R!!, R'? and R"’ are each as defined above , and finally selectively hydrolysing the carboxylic acid ester grouping -COOR" in these compounds to the carboxylic acid, or {b] reacting compounds of the general formula (XII) 0) 9
R X x our
Cee oo - HN r'" RR? XID) Cem em een
A R10 in which
AX T, R’, RI R! and R!? are each as defined above in the presence of a suitable reducing agent with compounds of the general formula (XI)
R-CHO (XI), in which
R!'7 represents hydrogen, (Cs-Cio)-aryl, 5- or 6-membered heteroaryl having up to three heteroatoms selected from the group consisting of N, O and §, or represents (C,-C3)-alkyl which for its part may be substituted by hydroxyl, trifluoromethoxy, (C;-Cs)-alkoxy or phenoxy, which for their part are optionally mono- or disubstituted by trifluoromethyl, or by (Cs-Cjo)-aryl or 5-
zs -24- to 6-membered heteroaryl having up to three heteroatoms from the group consisting of N, O and S, where all aryl and heteroaryl rings mentioned may for their part in each case be mono- to trisubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, (C;-Ce)-alkyl, } (C1-Ce)-alkoxy, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino, to give compounds of the general formula (XIV)
RY i : R' X
J Koo
HN rR" R% (XIV),
A R10 in which
AX T, R’, R'® R!, R'? and R'7 are each as defined above, then reacting these compounds in the presence of a base with compounds of the general formula (XV) 0
Y
Ro” XV)
R’ in which : R’, R" and Y are each as defined above to give compounds of the general formula (XVI)
0)
RS
RY X a. XK so 15 NO rR" R"™ XVI)
R=0O A 0 ’
R’ R in which
A,X, T,R” R%, RY R!" R'? R!® and R!7 are each as defined above, and finally selectively hydrolysing the carboxylic acid ester grouping -COOR" in these compounds to the carboxylic acid.
The entire process can also be carried out as solid-phase synthesis. In this case, the compounds of the general formula (VII) or (XII) are attached as carboxylic acid esters to a suitable support resin, the further reactions are carried out on solid phase and the target compound is finally cleaved off from the resin. Solid-phase synthesis and the attachment and the cleavage from the resin are customary standard techniques. To mention but one example from the extensive literature, reference is made to the publication "Linkers for Solid Phase Organic Synthesis", Ian W. James,
Tetrahedron 55, 4855-4946 (1999).
The reaction (VII) + (VII) — (IX) or (XII) + (XII) — (XIV) is carried out in the solvents which are customary for reductive amination and inert under the reaction conditions, if appropriate in the presence of an acid. The solvents include, for example, water, dimethylformamide, tetrahydrofuran, dichloromethane, dichloro- ethane, or alcohols such as methanol, ethanol, propanol, isopropanol or butanol; it is also possible to use mixtures of the solvents mentioned. Preference is given to methanol and ethanol in each case with addition of acetic acid.
Suitable reducing agents for the reaction (VI) + (VII) —» (IX) or (XI) + (XII) — (XIV) are complex aluminium hydrides or boron hydrides, such as, for example, diisobutylaluminium hydride, sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride or tetrabutylammonium borohydride, or else catalytic hydrogenation in the presence of transition metal catalysts such as, for example, palladium, platinum, rhodium or Raney nickel.
Preferred reducing agents are sodium cyanoborohydride, sodium triacetoxyborohydride and tetrabutylammonium borohydride.
The reaction (VII) + (VIII) — (IX) or (XII) + (XIII) — (XIV) is generally carried out in a temperature range of from 0°C to +40°C. =. ~The reaction (IX) + (X) = (XI) or (XIV) + (XV) = (XVI) is carried out in the = customary solvents which are inert under the reaction conditions. Preference is given to dimethylformamide, tetrahydrofuran and dioxane.
Suitable bases for the reaction (IX) + (X) — (XI) or (XIV) + (XV) — (XVI) are the customary inorganic or organic bases. Preference is given to triethylamine.
The reaction (IX) + (X) — (XI) or (XIV) + (XV) = (XVI) is generally carried out in a temperature range of from 0°C to +100°C.
The reaction (XI) — (II) or (XVI) = (II) is carried out in the solvents which are customary for ester cleavage and inert under the reaction conditions. In the case of the ester hydrolysis, these are preferably tetrahydrofuran, dioxane and alcohols, such as methanol and ethanol, in each case in a mixture with water. In the case of the cleavage of silyl esters, preference is given to using dioxane or tetrahydrofuran.
Suitable bases for the reaction (XI) — (II) or (XVI) — (II) are, in the case of the hydrolysis, the customary inorganic bases. Preference is given to lithium hydroxide,
zs -27- sodium hydroxide and potassium hydroxide. In the case of the cleavage of silyl esters, preference is given to using tetrabutylammonium fluoride.
The reaction (XI) — (II) or (XVI) — (I) is generally carried out in a temperature ’ 5 range of from 0°C to +100°C.
The compounds of the general formula (IV) correspond to the compounds of the general formula (IX) or (XIV) and can be prepared as described above.
The compounds of the general formulae (III), (V), (VI), (VID), (VID), (X), (XID), (XII) and (XV) are commercially available, known or can be prepared by customary methods [cf., for example, P.J. Brown et al, J. Med. Chem. 42, 3785-88 (1999)].
The compounds of the formula (I) according to the invention have a surprising and useful spectrum of pharmacological activity and can therefore be used as versatile medicaments. In particular, they are suitable for treating coronary heart diseases, for the prophylaxis of myocardial infarction and for the treatment of restenosis after coronary angioplasty or stenting. The compounds of the formula (I) according to the invention are preferably suitable for treating arteriosclerosis and hypercholesterolaemia, for increasing pathogenically low HDL levels and for lowering elevated triglyceride, fibrinogen and LDL levels. In addition, they can be used for treating obesity, diabetes, for treating the metabolic syndrome (glucose intolerance, hyperinsulinaemia, dyslipidaemia and high blood pressure owing to insulin resistance), hepatic fibrosis and cancer.
The activity of the compounds according to the invention can be examined, for example, in vitro by the transactivation assay described in the experimental section.
The activity of the compounds according to the invention in vivo can be examined, for example, by the tests described in the experimental section.
s -28-
Suitable administration forms for administering the compounds of the general formula (I) are all customary administration forms, i.e. oral, parenteral, inhalative, nasal, sublingual, rectal or external, for example transdermal, preferably oral or parenteral, administration forms. In the case of parenteral administration, particular mention has to be made of intravenous, intramuscular and subcutaneous administration, for example as a subcutaneous depot. Very particular preference is given to oral administration.
Here, the active compounds can be administered on their own or in the form of preparations. Preparations suitable for oral administration are, inter alia, tablets, capsules, pellets, sugar-coated tablets, pills, granules, solid and liquid aerosols, syrups, emulsions, suspensions and solutions. Here, the active compound has to be ~.- -. . - present in such an amount that a therapeutic effect is obtained. In general, the active =~ - compound can be present in a concentration of from 0.1 to 100% by weight, in particular from 0.5 to 90% by weight, preferably from 5 to 80% by weight. In particular, the concentration of active compound should be 0.5 — 90% by weight, i.e. the active compound should be present in amounts sufficient to reach the dosage range stated.
To this end, the active compounds can be converted in a manner known per se into the customary preparations. This is carried out using inert non-toxic pharmaceutically suitable excipients, auxiliaries, solvents, vehicles, emulsifiers and/or dispersants.
Auxiliaries which may be mentioned are, for example: water, non-toxic organic solvents, such as, for example, paraffins, vegetable oils (for example sesame oil), alcohols (for example ethanol, glycerol), glycols (for example polyethylene glycol), solid carriers, such as natural or synthetic ground minerals (for example talc or silicates), sugar (for example lactose), emulsifiers, dispersants (for example polyvinylpyrrolidone) and glidants (for example magnesium sulphate).
Claims (2)
1. Compounds of the general formula (I) Oo R\ RS 8 X 2 RR SCSor” R N rR" rR" N SA @, rR? l, Ie R10 R in which A represents a bond or represents a -CH,- or -CH,CH>- group, X represents O, S or CH,, R', R? and R? are identical or different and independently of one another each represents hydrogen, (C;-Ce)-alkyl, (C3-Cy)-cycloalkyl, hydroxyl, (C4-Ce)-alkoxy, (C6-Cip)-aryloxy, halogen, trifluoromethyl, trifluoromethoxy, (C;-Cs)-alkylaminosulphonyl, nitro or cyano, or R! and R? are attached to two adjacent carbon atoms and together with these form a fused cyclohexane or benzene ring, the latter optionally being substituted by a (C;-C,)-alkylsulphonylmethyl group, and rR? is as defined above, R* represents hydrogen or (C;-Cy)-alkyl,
oC - 148 - R® and R® represent hydrogen or together with the carbon atom to which they are attached form a carbonyl group, R’ represents hydrogen, (C,-C¢)-alkyl, phenyl or benzyl, where the aromatic radicals mentioned for their part may in each case be mono- to trisubstituted by identical or different substituents from the group consisting of (C1-Ce)-alkyl, (C;-Ce)-alkoxy, hydroxyl and halogen, R® represents hydrogen, (Cs-Cjo)-aryl or represents (C;-Cq4)-alkyl which for its part may be substituted by hydroxyl, trifluoromethoxy, (C;-Cq)- alkoxy or phenoxy, which for their part are optionally mono- or disubstituted by trifluoromethyl, or by (Cs-Co)-aryl or 5- or 6- membered heteroaryl having up to three heteroatoms from the group consisting of N, O and S, where all aryl and hetaroaryl rings mentioned may for their part in each case be mono- to trisubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, (C;-Cs)-alkyl, (C;-Ce)-alkoxy, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino,
R® and R'® are identical or different and independently of one another each represents hydrogen, (C;-Ce)-alkyl, (C;-Cg)-alkoxy, trifluoromethyl, trifluoromethoxy or halogen,
R' and R" are identical or different and independently of one another each represents hydrogen or (C;-Cg)-alkyl or together with the carbon atom to which they are attached form a (C4-Cy)-cycloalkyl ring,
and
R" represents hydrogen or represents a group which can hydrolysed and degraded to the corresponding carboxylic acid,
Co - 149 - and their pharmaceutically acceptable salts, hydrates and solvates.
2. Compounds of the general formula (I), in which A represents a bond or represents a -CH,- or -CH,CH,- group, X represents O, S or CH,, R', R? and R? are identical or different and independently of one another each represents hydrogen, (C;-Ce)-alkyl, (C;-Ce)-alkoxy, hydroxyl, halogen, trifluoromethyl, trifluoromethoxy, nitro or cyano, . R* represents hydrogen or (C;-C4)-alkyl, R’ and R® each represents hydrogen or together with the carbon atom to which they are attached form a carbonyl group, R’ represents hydrogen, (C;-Ce)-alkyl, phenyl or benzyl, in which the aromatic radicals mentioned for their part may in each case be mono- to trisubstituted by identical or different substituents from the group consisting of (C-Cg)-alkyl, (C;-C¢)-alkoxy, hydroxyl or halogen, R® represents hydrogen, (Cs-Cjo)-aryl or (Ci-Cy)-alkyl, which for its part is optionally substituted by (Ce-Cjg)-aryl or 5- or 6-membered heteroaryl having up to three heteroatoms from the group consisting of N, O and S, where all of the ring systems mentioned may for their part in each case be mono- to trisubstituted by identical or different substituents from the group consisting of halogen, hydroxyl, (C1-Ce)-
Co - 150 - alkyl, (C,-Ce)-alkoxy, trifluoromethyl, trifluoromethoxy, cyano, nitro and amino, R® and R'? are identical or different and independently of one another each represents hydrogen, (C;-Ce)-alkyl, (C;-Ce)-alkoxy, trifluoromethyl, trifluoromethoxy or halogen, RY and R" are identical or different and independently of one another each represents hydrogen or (C;-Ce)-alkyl, or together with the carbon atom to which they are attached they form a (C4-C;)-cycloalkyl ring, and RY represents hydrogen or a group that can be hydrolysed and degraded to the corresponding carboxylic acid, and their pharmaceutically acceptable salts, hydrates and solvates.
3. Compounds of the general formula (I) according to Claim 1 or 2, in which A represents a -CH,- or -CH,CH,- group, X represents O, S or CH», R', R? and R® are identical or different and independently of one another each represents hydrogen, (C;-Cy)-alkyl, (C,-C4)-alkoxy, chlorine, fluorine, trifluoromethyl, trifluoromethoxy, nitro or cyano, R* represents hydrogen or methyl,
Co - 151 - R® and RS each represent hydrogen or together with the carbon atom to which they are attached form a carbonyl group, R’ represents hydrogen, (C;-C,)-alkyl or benzyl, R® represents hydrogen, phenyl, benzyl or 5-membered heteroarylmethyl having up to two heteroatoms from the group consisting of N, O and S, where the aromatic ring systems mentioned for their part may in each case be mono- to trisubstituted by identical or different substituents from the group consisting of chlorine, fluorine, bromine, hydroxyl, (C-Cs)-alkyl, (C;-C4)-alkoxy, trifluoromethyl and amino, R® and R" are identical or different and independently of one another each represents hydrogen, (C;-Cs)-alkyl, (C;-Cs3)-alkoxy, trifluoromethyl, fluorine or chlorine, R'! and R" are identical or diffferent and independently of one another each represents hydrogen, methyl or ethyl, or together with the carbon atom to which they are attached they form a cyclopentyl or cyclohexyl ring, and R"” represents hydrogen or represents a group that can be hydrolysed and degraded to the corresponding carboxylic acid, and their pharmaceutically acceptable salts, hydrates and solvates.
4. Compounds of the general formula (I), according to Claim 1, 2 or 3 in which
CC - 152 -
A represents a -CH,- or -CH,CHs,- group,
X represents O, S or CH,
R! represents hydrogen, methyl or methoxy,
R? and R? are identical or different and independently of one another each represents methyl, trifluoromethyl, methoxy, trifluoromethoxy, chlorine or fluorine,
R* represents hydrogen,
: R’ and R® together with the carbon atom to which they are attached form a carbonyl group,
R’ represents methyl, ethyl, n-propyl or, in particular, hydrogen,
R® represents phenyl, furanylmethyl or thienylmethyl, where the ring systems mentioned for their part may in each case be mono- or disubstituted by identical or different substituents from the group consisting of methyl and ethyl,
R® and R'? are identical or different and each represents hydrogen or methyl in particular hydrogen,
R!! and R" are identical or different and each represents hydrogen or methyl g y in particular methyl, and oo - 153 - rR" represents a group which can be hydrolysed and degraded to the corresponding carboxylic acid, or, in particular, represents hydrogen, and their pharmaceutically acceptable salts, hydrates and solvates.
5. Compounds of the formula (IA) Oo R! 8 RZ 0 | Kon \ An, HC CH, (A), R® H in which A represents a ~-CHj;- or -CH,CH,- group, X represents O or S, R! represents hydrogen, methyl or methoxy, R? and R® are identical or different and independently of one another each represents methyl, isopropyl, tert-butyl, cyclohexyl, trifluoromethyl, methoxy, trifluoro-methoxy, chlorine or fluorine, and R® represents phenyl, furanylmethyl, thienylmethyl or oxazolylmethyl, where the ring systems mentioned for their part may in each case be mono- or disubstituted by methyl, or represents 2-methoxyethyl.
v Le A 34 838-Foreign Countries
6. Compounds of the formula (I) as defined in Claims 1 to 5 for the prophylaxis and treatment of diseases.
7. Medicaments, comprising at least one compound of the formula (I) as defined in Claim 1 and inert nontoxic, pharmaceutically suitable carriers, auxiliaries, E solvents, vehicles, emulsifiers and/or dispersants.
' . 8 Use of compounds of the formula (I) as defined in Claims 1 to 6 for preparing medicaments.
9. | Use of compounds of the formula (I) as defined in Claims 1 to 6 for preparing medicaments for the treatment of arteriosclerosis.
10. Process for preparing medicaments, characterized in that at least one compound of the formula (I) as defined in Claim 1 is converted into an administration form using auxiliaries and/or carriers. : -
11. Process for preparing compounds of the formula (I) as defined in Claim I, characterized in that [A] compounds of the general formula (II) (@) . "2 R° X 2s Kom HOOC N 1 12 TOA ROR (m, R’ R™ : in which me Ts AMENDED SHEET
A "Le A 34 838-Foreien Countries
A,X, R,R%, R®, R"", R" and R' are each as defined above : and . T represents benzyl, (C,-Ce)-alkyl or a polymeric support suitable . for solid-phase synthesis, . are initially, with activation of the carboxylic acid group in (II), reacted with compounds of the general formula (III) . R! ’ 2 oR NH, R', R? and R? are each as defined above, to give compounds of the general formula (la) R! OR Q R X _ R2 0 | xo T \ N NA R (Ta), R 10 R’ R in which
A le A 34 838-Foreign Countries A,X, TR, R% R3, RY, R®, R%, R'®, R" and R' are each as defined above, or [B] compounds of the general formula (IV)
O . R2 8 X TOYO er HN R" R'2 av), A R'° in which A,X, T,R% R% R!'% R' and R'? are each as defined above are, in the presence of a base, reacted with compounds of the general formula (V)
R! . R? 2 . N° Vv), H in which R', R%, R? and R’ are each as defined above - ‘ and : FRUIT AMENDED SHEET SRNIETHSLIEINE ts REET Q is a suitable leaving group,
‘ ) LeA34 838-Foreign Countries likewise to compounds of the general formula (Ia) : the compounds of the general formula (Ia) are, if appropriate according to known methods for amide alkylation or amide reduction, converted into compounds of the general formula (Ib) o i” 0 8 R? AVA “Som 1 12 Ra R R (Ib), R® l, I; R'° R* R in which : AX, T, RL REL R3 RY R% RS, RY, RE, RY, R', RY and R'Z are each as defined above, then converted with acids or bases into the corresponding carboxylic acids of a 10 : the general formula (Ic) : R! RS 0 N 5 nt R® X RZ R | OH N 1 12 A A Es HEC R R* R’ R in which © AX RLRL RL RORY RS RY, RY RY, RY, R' and RY are each as defined above, EERE olen AMENDED SHEET
) Cl "leads 838-Foreign Countries | E and these are, if appropriate according to known methods for esterification, modified further by reaction with compounds of the general formula (VI) RP-Z (VD, in which RY” is as defined above and : Z represents a suitable leaving group or represents a hydroxyl group.
12. Use according to Claim 9 for preparing medicaments for the treatment of arteriosclerosis, for increasing pathologically low HDL levels and for reducing elevated triglyceride and LDL levels in cases of arteriosclerosis and/or hypercholesterolaemia.
13. Compounds of the formula (II) RY 1 . 8 X Foye HOOC.__N "Rr" ART tH R R in which © AX, RR, R% RY, RY and R" are as defined in Claims 1 to S, and So Tons ie - ~ T; represents benzyl, (C;-Cs)-alkyl or a polymeric support suitable for REG RINNC SAE solid-phase synthesis. RIE oo AMENDED SHEET oo - 159 -
16. Compounds of the formula (II) RY 1 8 X ase Hooc.__N nt Rr" R’ R in which A,X, R7,R%, R%, R'%, R" and R'? are as defined in Claims 1 to 5, and : T represents benzyl, (C;-Ce)-alkyl or a polymeric support suitable for solid-phase synthesis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10049208 | 2000-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200302610B true ZA200302610B (en) | 2004-04-05 |
Family
ID=7658699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200302610A ZA200302610B (en) | 2000-10-05 | 2003-04-03 | Propionic acid derivatives with PPAR-alpha activating properties |
Country Status (9)
Country | Link |
---|---|
KR (1) | KR20030059175A (en) |
AR (1) | AR035203A1 (en) |
DE (1) | DE10124905A1 (en) |
DO (1) | DOP2001000260A (en) |
EC (1) | ECSP034536A (en) |
GT (1) | GT200100198A (en) |
PE (1) | PE20020475A1 (en) |
SV (1) | SV2002000677A (en) |
ZA (1) | ZA200302610B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2005141516A (en) | 2003-06-06 | 2007-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | ANILINE DERIVATIVES |
KR100699928B1 (en) | 2004-10-05 | 2007-03-26 | 재단법인서울대학교산학협력재단 | Process for preparing the intermediate compounds for ppar ? ligands |
-
2001
- 2001-05-22 DE DE10124905A patent/DE10124905A1/en not_active Withdrawn
- 2001-09-24 KR KR10-2003-7004828A patent/KR20030059175A/en not_active Application Discontinuation
- 2001-09-28 AR ARP010104593A patent/AR035203A1/en not_active Application Discontinuation
- 2001-10-01 GT GT200100198A patent/GT200100198A/en unknown
- 2001-10-04 DO DO2001000260A patent/DOP2001000260A/en unknown
- 2001-10-04 SV SV2001000677A patent/SV2002000677A/en unknown
- 2001-10-04 PE PE2001000987A patent/PE20020475A1/en not_active Application Discontinuation
-
2003
- 2003-04-03 EC EC2003004536A patent/ECSP034536A/en unknown
- 2003-04-03 ZA ZA200302610A patent/ZA200302610B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP034536A (en) | 2003-05-26 |
GT200100198A (en) | 2002-06-25 |
DE10124905A1 (en) | 2002-04-11 |
DOP2001000260A (en) | 2002-12-15 |
AR035203A1 (en) | 2004-05-05 |
PE20020475A1 (en) | 2002-06-08 |
KR20030059175A (en) | 2003-07-07 |
SV2002000677A (en) | 2002-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5105297B2 (en) | PPAR activity regulator | |
US20090170911A1 (en) | Novel azole compound | |
JP7328962B2 (en) | Polycyclic carbamoylpyridone derivatives | |
JP7353707B2 (en) | Polycyclic pyridone derivative | |
NZ523034A (en) | Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament | |
WO2006043655A1 (en) | Medicinal composition for inhalation | |
EP2217283A2 (en) | Biocompatible biodegradable fumagillin analog conjugates | |
JPWO2002100819A1 (en) | N-arylphenylacetamide derivatives and pharmaceutical compositions containing them | |
JPH08508027A (en) | Natural amino acid derivatives that are inhibitors of metalloproteinases | |
JP2948658B2 (en) | Novel amino acid derivative, production method thereof and pharmaceutical composition thereof | |
US9303027B2 (en) | Kappa opioid receptor agonists | |
US6803480B2 (en) | Diphenylmethane derivatives | |
WO2021107065A1 (en) | Polycyclic pyridopyrazine derivative | |
JP2023182723A (en) | Pharmaceutical composition containing polycyclic carbamoylpyridone derivative | |
JP2009040777A (en) | Plasminogen activator inhibitor-1 inhibiting agent | |
KR100718906B1 (en) | Dihydronaphthalene derivative compounds and drugs containing these compounds as the active ingredient | |
ZA200302610B (en) | Propionic acid derivatives with PPAR-alpha activating properties | |
WO2020246503A1 (en) | Cyclic amide compounds for rabies treatment and method thereof | |
WO2023158679A2 (en) | Thiostrepton-inspired compounds for treatment of cancer and preparation thereof | |
KR20150079616A (en) | Inhibitors of beta-hydrolase for treatment of cancer | |
US10385045B2 (en) | Compound having EP2 agonist activity | |
JPWO2005061492A1 (en) | Nitrogen-containing heterocyclic compounds and drugs containing them as active ingredients | |
JP2001509790A (en) | Metalloproteinase inhibitors | |
US20070185183A1 (en) | Indolinesulphanilic acid amides as ppar-delta modulators | |
WO2023249007A1 (en) | Calpain inhibitor |